In summary, our findings demonstrated that SNHG1 contributed to tumor progression and cisplatin resistance in breast cancer cells through epigenetically silence miR-381 via recruiting EZH2 on the promotor of miR-381, which may provide a novel mechanism and therapeutic target for breast cancer chemotherapy. Here, EZH2 is linked to breast carcinoma.